A clinical trial of a vaccine meant to prevent and slow the progression of Alzheimer's is about to begin at a Boston hospital.
The trial was called a "remarkable milestone" by the research lead.
He said that there was evidence suggesting the potential of the vaccine for AD. If clinical trials show that the vaccine is safe and effective, it could represent a treatment for people with Alzheimer's and it could also be given early to help prevent Alzheimer's in people at risk.
The FDA approved the first new Alzheimer's drug in 20 years, called Aduhelm.
Protollin is an experimental substance that has been used in other vaccines for many years.
Protollin can clear the plaques of the Alzheimer's disease-linked amyloid in the brain.
The vaccine harnesses a novel arm of the immune system to treat AD. Research in this area has paved the way for us to pursue a whole new avenue for potentially treating not only AD, but also other neurodegenerative diseases.
16 people who are 60 and 85 years old are participating in the trial to determine the safety of the vaccine.
The vaccine could be used to fight the most common cause of dementia, but it will take years of clinical trials to see if it works.
The first human trial of a vaccine for Alzheimer's disease is about to start.
FDA Advisors Resign to Protest Approval of Alzheimer's Drug that They Say Doesn't Work
Are you interested in supporting clean energy adoption? UnderstandSolar.com can show you how much money you could save by using solar power. Futurism.com may receive a small commission if you sign up through this link.
